Drug class profile · refreshed daily from federal data

Aldosterone Antagonist

3 molecules in this class, $164.5M combined CY2024 Part D spend across 14.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Aldosterone Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $164.5Mcombined across class
Total Rx claims: 14.5M4.7M unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Spironolactone

Brand: Aldactone · 14.0M Part D claims (CY24) · 4.5M beneficiaries · First FDA approval: 1960-01-21

12 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.044

→

Avg plan cost$0.203

Part D spend $122.9M 5× spread, current vs floor

Class share

75%

of class CY24 spend

View profile →

Eplerenone

Brand: Inspra · 507K Part D claims (CY24) · 165K beneficiaries · First FDA approval: 2002-09-27

8 generic mfrs 0 plans require PA

Low NADAC$0.309

→

Avg plan cost$0.825

Part D spend $41.6M 3× spread, current vs floor

Class share

25%

of class CY24 spend

View profile →

Carospir

— Part D claims (CY24) · First FDA approval: 2017-08-04

Brand-only (no generics)

Low NADAC$3.45

→

Avg plan cost$3.45

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.